Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of egyptian patients with hepatitis C virus infection

Infectious Disorders - Drug Targets

Volumn 17, Issue 2, 2017, Pages 95-100

  Ahmed, Ossama A ^a   Kaisar, Hany H ^a   Hawash, Nehad ^b   Samir, Hossam ^a   Sha Bana, Sherif S T ^a   Fouad, Mohamed Hassan A ^a   Rizk, Fatma ^b   Abd Elsalam, Sherief ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

Egypt; HCV; PCR; Pegylated interferon; Ribavirin; Sofosbuvir; Virological

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; VIRUS RNA;

ADULT; ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; OPEN STUDY; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; EGYPT; GENETICS; GENOTYPE; HEPACIVIRUS; VIROLOGY;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR;

EID: 85027887507     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526517666170417143216     Document Type: Article

References (19)

1. Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect., 2011, 17,107–115.
2. Breban, R.; Doss, W.; Esmat, G. Towards Realistic Estimates of HCV Incidence in Egypt. J. Viral. Hepat., 2013, 20, 294-296.
3. Gower, E.; Estes, C.; Blach, S. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol., 2014, 61, 45-57.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol., 2011, 55, 245-264.
5. Manns, M.P.; McHutchison, J.G.; Gordon, S.C. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358, 958-965.
6. Chung, R.T. A watershed moment in the treatment of hepatitis. C. N. Engl. J. Med., 2012, 366, 273-275.
7. Muir, A.J.; Provenzale, D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J. Clin. Gastroenterol., 2002, 34, 268-227.
8. Kohli, A.; Shaffer, A.; Sherman, A.; Kottilil, S. Treatment of Hepatitis C; A Systematic Review. JAMA, 2014, 312, 631-640.
9. Bourliere, M.; Khaloun, A.; Wartelle-Bladou, C.; Chronic hepatitis C: treatments of the future. Clin. Res. Hepatol. Gastroenterol., 2011, 35, 84-95.
10. El-Fishawy, H.; Saadi, G.; Hassaballa, M.; Antiviral treatment prioritization in HCV-infected patients with ex-trahepatic manifestations - An Egyptian perspective. J. Adv. Res., 2016, 7(3), 391-402.
11. Gentile, I.; Scotto, R.; Zappulo, E. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert. Opin. Investig. Drugs, 2016, 25(5), 557-572.
12. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden. J. Viral. Hepat., 2014, 21,1-4.
13. Elwan, N.; Elfert, A.; Abd-Elsalam, S. Study of hepatic Steatosis index in patients with chronic HCV infection. Int. J. Curr. Microbiol. App. Sci., 2014, 5(5), 266-274.
14. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol., 2017, 66 (1),153-194.
15. Gentile, I.; Maraolo, A.E.; Niola, M.; Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Rev. Gastroenterol. Hepatol., 2016, 10(11), 1227-1234.
16. Foster, R.G.; Pianko, S.; Brown, A. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-Alfa in patients with hepatitis C virus genotype3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 Infection. Gastroenterology, 2015, 149, 1462-1470.
17. Lawitz, E.; Poordad, F.; Brainard, M.D. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology, 2015, 61(3), 769-775.
18. Doss, W.; Shiha, G.; Hassany, M. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J. Hepatol., 2015, 63, 581-585.
19. Gane, E.J.; Stedman, C.A.; Hyland, R.H. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl. J. Med., 2013, 368, 34-44.